Beyond NMDA Receptors: A Narrative Review of Ketamine’s Rapid and Multifaceted Mechanisms in Depression Treatment
Open accessThe DOI matches its Crossref record; 224 of the 225 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
The rising prevalence of depression, with its associated suicide risk, demands effective fast-acting treatments. Ketamine has emerged as promising, demonstrating rapid antidepressant effects. While early studies show swift mood improvements, its precise mechanisms remain unclear. This article aims to compile and synthesize the literature on ketamine’s molecular actions. Ketamine primarily works by antagonizing NMDA receptors, reducing GABAergic inhibition, and increasing glutamate release. This enhanced glutamate activates AMPA receptors, triggering crucial downstream cascades, including BDNF-TrkB and mTOR pathways, promoting synaptic proliferation and regeneration. Moreover, neuroimaging studies have demonstrated alterations in brain networks involved in emotional regulation, including the Default Mode Network (DMN), Central Executive Network (CEN), and Salience Network (SN), which are frequently disrupted in depression. Despite the promising findings, the literature reveals significant inaccuracies and gaps in understanding the full scope of ketamine’s therapeutic potential. For instance, ketamine engages with opioid receptors, insinuating a permissive role of the opioid system in amplifying ketamine’s antidepressant effects, albeit ketamine does not operate as a direct opioid agonist. Further exploration is requisite to comprehensively ascertain its safety profile, long-term efficacy, and the impact of genetic determinants, such as BDNF polymorphisms, on treatment responsiveness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TrkB activation triggers ERK and mTORC1 cascades, extends protein synthesis windows, and supports dendritic spine maturation”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [56]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Esketamine provides a more NMDAR-centered entry into the induction pathway described above, producing rapid clinical effects but also transient dissociation and sympathomimetic effects [45,46,47,49,52,55,56].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [56]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–225 of 225
Caliman-Fontesa, A. T., Leal, G. C., Correia-Melo, F. S., Paixão, C. S., Carvalho, M. S., Jesus-Nunes, A. P., Vieira, F., Magnavita, G., Bandeira, I. D., Mello, R. P., et al. (2023) · Trends in Psychiatry and Psychotherapy · doi:10.47626/2237-6089-2021-0298 · Cited by 14
Jiang, Q., Qi, Y., Zhou, M., Dong, Y., Zheng, W., Zhu, L., Li, Y., Zhou, H., & Wang, L. (2024) · BMC Anesthesiology · doi:10.1186/s12871-024-02681-9 · Cited by 14
Sandbaumhüter, F. A., & Thormann, W. (2018) · Electrophoresis · doi:10.1002/elps.201800012 · Cited by 13
Sant, L. C. D., Sarin, L. M., Lucchese, A. C., Magalhães, E. T. P., Tuena, M. A., Nakahira, C., Porto, J. A. D., Lacerda, A. L. T., & Mari, J. D. J. (2022) · Pharmaceuticals · doi:10.3390/ph16010031 · Cited by 13
Fullana, M. N., Paz, V., Artigas, F., & Bortolozzi, A. A. (2021) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2021.09.002 · Cited by 12
Scotton, E., Casa, P. L., de Abreu, F. P., Silva, S. D. Á. E., Wilges, R. L. B., Rossetto, M. V., Géa, L. P., Rosa, A. R., & Colombo, R. (2023) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2023.173523 · Cited by 12
Li, W., Chen, L., Su, T., Li, C., Lin, W., Wu, H.-J., Tsai, S., Bai, Y., Tu, P., & Chen, M. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.05.024 · Cited by 12
Gałecki, P., Bliźniewska-Kowalska, K. M., Cubała, W. J., Depukat, A., Mosiołek, A., RYBAKOWSKI, J. K., Samochowiec, J., Sobolewski, B., Szulc, A., & Dudek, D. (2024) · Psychiatria Polska · doi:10.12740/pp/189494 · Cited by 12
Zhang, Q., Wu, J., Pei, C., Ma, M., Dong, Y., Gao, M. J., & Zhang, H. (2022) · Biological Psychology · doi:10.1016/j.biopsycho.2022.108426 · Cited by 11
Meiering, M. S., Weigner, D., Gärtner, M., Carstens, L., Keicher, C., Hertrampf, R., Beckmann, C. F., Mennes, M., Wunder, A., Weigand, A., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03120-6 · Cited by 9
TRKB interaction with PSD95 is associated with latency of fluoxetine and 2R,6R‐hydroxynorketamine
Fred, S. M., Moliner, R., Antila, H., Engelhardt, K., Schlüter, O. M., Casarotto, P. C., & Ċastrén, E. (2023) · European Journal of Neuroscience · doi:10.1111/ejn.15952 · Cited by 7
Wang, Y., Zhou, J., Chen, X., Liu, R., Zhang, Z., Feng, L., Feng, Y., Wang, G., & Zhou, Y. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.01.115 · Cited by 7
Davydova, N. Y., Hutner, D. A., Gaither, K. A., Singh, D. K., Prasad, B., & Davydov, D. R. (2023) · Biology · doi:10.3390/biology12081055 · Cited by 7
Talebian, A., Robinson-Brookes, K., & Meakin, S. O. (2018) · Journal of Molecular Neuroscience · doi:10.1007/s12031-018-1214-z · Cited by 6
Burrows, M., Kotoula, V., Dipasquale, O., Stringaris, A. K., & Mehta, M. A. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231189432 · Cited by 6
Caliman‐Fontes, A. T., Leal, G. C.-G., Correia‐Melo, F. S., Paixão, C. S., Carvalho, M. S., Jesus‐Nunes, A. P., Vieira, F., Magnavita, G. M., Bandeira, I. D., Mello, R. P., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22187904 · Cited by 6
La kétamine : un neuropsychotrope au mécanisme d’action innovant
Guilloux, J., Nguyen, T. M. L., & Gardier, A. M. (2023) · Biologie Aujourd hui · doi:10.1051/jbio/2023026 · Cited by 5
The quest for optimal ketamine dosing formula in treatment-resistant major depressive disorder
Kwaśna, J., Cubała, W. J., Kwaśny, A., & Wilkowska, A. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00637-x · Cited by 5
Davydova, N. Y., Hutner, D. A., Gaither, K. A., et al. (2023) · Preprints.org · doi:10.20944/preprints202306.1602.v1 · Cited by 3
Concerns on the Use of Ketamine in the Treatment of Depression
Barik, A. K., Chauhan, R., Reddy, A., & Kaloria, N. (2023) · Indian Journal of Psychological Medicine · doi:10.1177/02537176231201660 · Cited by 3
Mansoor, S., Khan, K. H., & Faridi, M. A. (2023) · Journal of Pakistan Psychiatric Society · doi:10.63050/jpps.20.01.189 · Cited by 3
Rasool, U., Jan, N., Zahoor, M., Roub, F., Rather, Y. H., Hussain, A., & Najeeb, R. (2023) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20230029 · Cited by 2
A Review of the Metabolism and Relevance to Form and Formulation of Ketamine
Chue, P. S., Andreiev, A., Chue, J., Chue, J., & Tate, M. (2023) · European Psychiatry · doi:10.1192/j.eurpsy.2023.1783 · Cited by 2
Cannarozzo, C., Rubiolo, A., Casarotto, P., & Castrén, E. (2022) · doi:10.1101/2022.04.06.487292 · Cited by 2
Jeong, G., & Paolini, M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.30.505423 · Cited by 1
Research works printed but not linked: 1
- Delgado P.L. Depression: The case for a monoamine deficiency J. Clin. Psychiatry 2000 61 (Suppl. S6) 7 11 10775018
Cited by
Nagpurkar, K., Ghive, P., Kale, M. B., Nistane, N. T., Taksande, B. G., Umekar, M. J., & Trivedi, R. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.05.022 · Cited by 12
Molecular Mechanisms of Depression: The Interplay Between Genes and Receptors
Oatu, A., Trifu, S. C., & Coman, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311325 · Cited by 10
Azadbakht, A. A., Mashayekhi‐Sardoo, H., & Baghcheghi, Y. (2025) · Neurochemical Research · doi:10.1007/s11064-025-04619-0 · Cited by 6
Yao, Z., Godje, I. S. G., Jiao, B., Shen, L., & Luo, S. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103153 · Cited by 6
Is the antidepressant efficacy of ketamine and esketamine mediated via opioid mechanisms?
Lu, A., Xu, H., Le, G. H., Dri, C. E., Wong, S., Ho, R., Cao, B., Lo, H. K. Y., Rhee, T. G., Yin, L., et al. (2026) · European Psychiatry · doi:10.1192/j.eurpsy.2026.10157 · Cited by 6
Metadata
- Authors
- Antos, Z., Żukow, X., Bursztynowicz, L., & Jakubów, P.
- Affiliations
- Medical University of Białystok (PL)
- Corresponding author
- Jakubów, Piotr
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-12-20
- Volume
- 25
- Issue
- 24
- Pages
- 13658
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC11728282
- OpenAlex
- W4405695206
- Cited by
- 21
- References
- 225
- Citations by year
- 2026: 15 · 2025: 6
- FWCI
- 1.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, depression, rapid-acting antidepressants, NMDA receptor antagonism, glutamate, AMPA receptors, BDNF/TrkB signaling, mTOR signaling, synaptic plasticity, default mode network, frontoparietal network, salience network, opioid receptors, BDNF polymorphism, treatment response
- MeSH terms
- Animals, Antidepressive Agents, Brain, Depression, Humans, Ketamine, Receptors, N-Methyl-D-Aspartate, Brain-Derived Neurotrophic Factor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.